Pathophysiology of heart failure following myocardial infarction

Heart

Volumn 91, Issue SUPPL. 2, 2005, Pages

  Struthers, Allan D ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; SPIRONOLACTONE; STATINE DERIVATIVE; TRANDOLAPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; ENDOTHELIUM LESION; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SUDDEN DEATH; VASCULAR DISEASE;

ALDOSTERONE; ANGIOTENSINS; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 17644364787     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.062034     Document Type: Conference Paper

References (17)

1. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
2. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004;90:765-70.
3. Farquharson C, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo - Evidence for an aldosterone induced vasculopathy. Clin Sci 2002;103:425-31.
4. Heymes C, Garnier A, Fuchs S, et al. Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. Mol Cell Endocrinol 2004;217:213-9.
5. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-6.
6. Rocha R, Rudolph AE, Frierdich GE. Aldosterone induces a vascular inflammatory pnenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10.
7. Sun Y, Ratajska A, Zhou G, et al. Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993;122:395-403.
8. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992;20:67-73.
9. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104:137-9.
10. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-14.
11. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72.
12. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10.
13. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
14. Schafer A, Fraccarollo D, Hildemann SK, et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003;58:655-62.
15. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65.
16. Pitt B, Zannad F, Remme WJ, et al for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
17. Pitt B, Remme W, Zannad F, et al for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.